Notably, the migration and invasion abilities of HCC cells were enhanced after treatment with a low concentration of sorafenib (1 μm); however, no enhancement was observed in cells with LARP4B knockdown (Fig. 4E). Here, LARP4B is linked to hepatocellular carcinoma.